KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Change in Cash data on record, last reported at $74.5 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 85.98% year-over-year to $74.5 million; the TTM value through Dec 2025 reached $194.5 million, up 907.19%, while the annual FY2025 figure was $194.5 million, 907.19% up from the prior year.
  • Change in Cash reached $74.5 million in Q4 2025 per AMRX's latest filing, down from $154.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $154.7 million in Q3 2025 and bottomed at -$172.7 million in Q2 2021.
  • Average Change in Cash over 5 years is -$1.7 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 728.24% in 2023, then skyrocketed 1045.0% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$53.9 million in 2021, then dropped by 12.59% to -$60.7 million in 2022, then skyrocketed by 105.77% to $3.5 million in 2023, then surged by 1045.0% to $40.1 million in 2024, then surged by 85.98% to $74.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $74.5 million in Q4 2025, $154.7 million in Q3 2025, and $15.3 million in Q2 2025.